Clinical Trial Update: Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated lower-dose or standard-dose regorafenib in patients with refractory metastatic colorectal cancer, with results posted after completion…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Stivarga (regorafenib)

Snippet

Sponsor: Academic and Community Cancer Research United | Conditions: Colon Adenocarcinoma, Rectal Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2019-07-26